Lucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Update

Lucid Diagnostics Inc. (NASDAQ:LUCD) saw a significant growth in short interest during the month of January. As of January 30th, there was short interest totaling 7,014,153 shares, a growth of 84.7% from the January 15th total of 3,797,518 shares. Currently, 5.5% of the company’s stock are sold short. Based on an average trading volume of 4,345,378 shares, the short-interest ratio is presently 1.6 days. Based on an average trading volume of 4,345,378 shares, the short-interest ratio is presently 1.6 days. Currently, 5.5% of the company’s stock are sold short.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LUCD. Cubist Systematic Strategies LLC purchased a new position in Lucid Diagnostics in the 1st quarter valued at $39,000. Goldman Sachs Group Inc. lifted its stake in shares of Lucid Diagnostics by 35.7% in the first quarter. Goldman Sachs Group Inc. now owns 86,302 shares of the company’s stock worth $129,000 after buying an additional 22,727 shares in the last quarter. Geode Capital Management LLC boosted its position in Lucid Diagnostics by 420.3% during the second quarter. Geode Capital Management LLC now owns 1,577,369 shares of the company’s stock worth $1,814,000 after acquiring an additional 1,274,194 shares during the last quarter. Intech Investment Management LLC acquired a new position in Lucid Diagnostics during the second quarter worth about $42,000. Finally, JPMorgan Chase & Co. grew its stake in Lucid Diagnostics by 71,026.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 32,718 shares of the company’s stock valued at $38,000 after acquiring an additional 32,672 shares in the last quarter. 74.01% of the stock is currently owned by institutional investors and hedge funds.

Lucid Diagnostics Trading Up 9.0%

Shares of LUCD stock traded up $0.11 during mid-day trading on Friday, reaching $1.33. The stock had a trading volume of 883,791 shares, compared to its average volume of 2,593,260. The business’s fifty day moving average is $1.16 and its 200-day moving average is $1.13. The firm has a market cap of $183.11 million, a price-to-earnings ratio of -1.28 and a beta of 1.22. Lucid Diagnostics has a 1-year low of $0.95 and a 1-year high of $1.80.

Lucid Diagnostics (NASDAQ:LUCD) last issued its earnings results on Wednesday, November 12th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.04). The company had revenue of $1.21 million during the quarter, compared to analysts’ expectations of $1.35 million. On average, analysts forecast that Lucid Diagnostics will post -0.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Wall Street Zen downgraded Lucid Diagnostics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lucid Diagnostics in a research report on Monday, December 29th. Needham & Company LLC reissued a “buy” rating and issued a $3.00 price target on shares of Lucid Diagnostics in a report on Thursday, November 13th. Finally, Ascendiant Capital Markets upped their price objective on shares of Lucid Diagnostics from $8.00 to $8.25 and gave the company a “buy” rating in a report on Wednesday, December 10th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $3.94.

Lucid Diagnostics Company Profile

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.